BWXT Medical Submits Drug Master File for Actinium-225 API to U.S. Food and Drug Administration
(OTTAWA, Ontario – June 7, 2024) – BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient. Ac-225 is an alpha-emitting isotope used in targeted alpha therapies (TATs) that combine the isotope with specific tumor-seeking targeting vectors […]
